NVO250110P87000
- 0.75
- 0.000.00%
Novo-Nordisk A/S Newsroom
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly. -- Barrons.com
Sales are disappointing, and the market scale is questionable....... The trade of overseas weight-loss drug stocks is cooling down.
Due to disappointing clinical trial results for new drugs and sales data below expectations for two consecutive quarters, the stock prices of Novo-Nordisk A/S and Eli Lilly and Co have fallen from their historical highs. Novo-Nordisk A/S has missed out on the top spot in the European stock market, and stocks related to weight loss drugs have entered bear market territory.
Novo Nordisk Very Interested in Small Nuclear Reactors, Chairman Says -- Market Talk
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
IMMvention Therapeutix Enters Collaboration With Novo Nordisk for Sickle Cell Disease Therapies
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
Novo Nordisk to Further Scale Up Production, Supply, Employment -- Market Talk
GLP-1 Weight Loss Drugs Linked to a Wide Range of Health Benefits and Risks: Study
$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
CFRA Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Cuts Target Price to $90
Research: Weight loss drugs can also reduce the risk of Alzheimer's.
Recently, a large-scale study on popular weight loss drugs showed that patients using GLP-1 medications (such as Novo-Nordisk A/S's Ozempic and Wegovy, and Eli Lilly and Co's Mounjaro) had a 12% reduced risk of developing Alzheimer's disease, but there was an increase in the risk of arthritis, kidney, and pancreatic diseases.
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
LVMH Is Once Again the Largest Company in Europe by Market Cap
U.S. Stock Gold Mining | Led by UBS Group! Multiple banking giants in the U.S. stock market hit new highs; join the Spring Festival "gift battle"! JD.com surged over 10% overnight.
It may be acquired by a mysterious buyer! Intel surged more than 9% in the last trading day and continued to rise over 3% in after-hours trading; Credo rose nearly 6%, up more than 19% since early 2025, hitting a record high.
Why Did Novo Nordisk (NVO) Go Down on Friday?
Trending Stocks as Wall Street Bounces Back With Strong Week
Express News | JPMorgan Analyst Richard Vosser: (In the context of negotiations in the USA to lower Pharmaceutical prices) expects that Novo-Nordisk A/S weight loss drugs Ozempic and Rybelsus will see a net discount of 50% on about 30% of their sales in the Medicare Par
Express News | Novo-Nordisk A/S: The 3rd phase clinical trial of 7.2mg semaglutide achieved its primary endpoint, with a 20.7% weight loss at 72 weeks.
The king of Luxury Goods returns: LVMH surpasses Novo-Nordisk A/S, reclaiming the top spot in Europe's Market Cap.
①LVMH's market value surpasses Novo-Nordisk A/S, regaining the title of the most valuable Listed in Hong Kong company in Europe; ②LVMH's stock price fell 13% last year, but signs of Industry recovery and positive earnings reports from peers have raised expectations, leading analysts at Bank of America to upgrade LVMH's rating to 'Buy'; ③Novo-Nordisk A/S is affected by multiple factors including supply and Pharmaceutical pricing concerns, an increasingly competitive environment, and disappointing results from experimental drug trials.